| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT05139004) | City of Hope Medical Center | 2022-07-19 |
| A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS (NCT05448599) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2022-07-08 |
| G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT (NCT05453552) | Nanfang Hospital, Southern Medical University | 2022-07-01 |
| Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (NCT05316701) | Orca Biosystems, Inc. | 2022-06-21 |
| Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (NCT03399773) | Fred Hutchinson Cancer Center | 2022-05-10 |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study (NCT04726241) | PedAL BCU, LLC | 2022-04-18 |
| Off-the-shelf NK Cells + SCT for Myeloid Malignancies (NCT05115630) | M.D. Anderson Cancer Center | 2022-04-08 |
| Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT (NCT05823714) | The First Affiliated Hospital of Soochow University | 2022-01-20 |
| Two Step Haplo With Radiation Conditioning (NCT05031897) | Thomas Jefferson University | 2021-10-25 |
| Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS (NCT04708054) | M.D. Anderson Cancer Center | 2021-10-21 |
| A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) (NCT05061147) | Maxinovel Pty., Ltd. | 2021-09-16 |
| ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT05010122) | M.D. Anderson Cancer Center | 2021-07-08 |
| Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (NCT04734990) | M.D. Anderson Cancer Center | 2021-07-07 |
| A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome (NCT04900350) | Akeso | 2021-06-18 |
| MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies (NCT04762875) | Ensoma | 2021-06-16 |
| Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study (NCT05972577) | Ohio State University Comprehensive Cancer Center | 2021-06-11 |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation (NCT03602898) | Fred Hutchinson Cancer Center | 2021-06-01 |
| Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML (NCT04842604) | Pfizer | 2021-05-17 |
| A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) (NCT04691141) | Shanghai Antengene Corporation Limited | 2021-02-23 |
| Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (NCT04279847) | Incyte Corporation | 2021-02-23 |
| Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders (NCT04761770) | Memorial Sloan Kettering Cancer Center | 2021-02-15 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (NCT04195633) | Fred Hutchinson Cancer Center | 2021-01-25 |
| Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (NCT04655755) | M.D. Anderson Cancer Center | 2021-01-19 |
| CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT04493164) | M.D. Anderson Cancer Center | 2020-12-30 |
| National Longitudinal Cohort of Hematological Diseases (NCT04645199) | Institute of Hematology & Blood Diseases Hospital, China | 2020-12-01 |
| Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study (NCT04537871) | City of Hope Medical Center | 2020-11-18 |
| Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation (NCT04339101) | City of Hope Medical Center | 2020-11-11 |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies (NCT03272633) | Rutgers, The State University of New Jersey | 2020-10-26 |
| Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization (NCT04439006) | Jennifer Woyach | 2020-10-23 |
| 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II (NCT03941769) | M.D. Anderson Cancer Center | 2020-09-29 |
| SARS-CoV-2 Donor-Recipient Immunity Transfer (NCT04666025) | City of Hope Medical Center | 2020-09-23 |
| A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia (NCT04239157) | M.D. Anderson Cancer Center | 2020-08-25 |
| A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies (NCT04227847) | Seagen, a wholly owned subsidiary of Pfizer | 2020-08-07 |
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations (NCT04493138) | M.D. Anderson Cancer Center | 2020-07-21 |
| Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) (NCT04278768) | Curis, Inc. | 2020-07-06 |
| Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory (NCT03969446) | City of Hope Medical Center | 2020-05-04 |
| TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT (NCT04281199) | City of Hope Medical Center | 2020-02-28 |
| Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia (NCT04262843) | City of Hope Medical Center | 2020-02-07 |
| A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT04243785) | Edgewood Oncology Inc. | 2020-01-06 |
| Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT (NCT03066466) | Loyola University | 2019-12-10 |
| Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation (NCT04060277) | City of Hope Medical Center | 2019-11-27 |
| Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (NCT04167696) | Celyad Oncology SA | 2019-11-25 |
| Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome (NCT04160052) | M.D. Anderson Cancer Center | 2019-10-01 |
| ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT04013880) | Vanderbilt-Ingram Cancer Center | 2019-08-27 |
| AZD6738 for Patients With Progressive MDS or CMML (NCT03770429) | Massachusetts General Hospital | 2019-08-05 |
| Early Palliative Care for Patients With Haematological Malignancies (NCT03800095) | University Hospital, Clermont-Ferrand | 2019-03-14 |
| A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant (NCT03739502) | University of Rochester | 2019-02-28 |
| Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT03862157) | M.D. Anderson Cancer Center | 2019-02-27 |
| Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant (NCT03438344) | City of Hope Medical Center | 2018-12-01 |
| Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (NCT03672539) | M.D. Anderson Cancer Center | 2018-11-07 |
| Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome (NCT03661307) | M.D. Anderson Cancer Center | 2018-10-31 |
| QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML (NCT03365661) | Masonic Cancer Center, University of Minnesota | 2018-10-30 |
| Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy (NCT03630991) | M.D. Anderson Cancer Center | 2018-10-11 |
| Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT03600155) | M.D. Anderson Cancer Center | 2018-10-11 |
| Resiliency in Older Adults Undergoing Bone Marrow Transplant (NCT04188678) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-09-28 |
| Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation (NCT03683433) | M.D. Anderson Cancer Center | 2018-09-18 |
| CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant (NCT03560752) | City of Hope Medical Center | 2018-08-20 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies (NCT03465540) | Amgen | 2018-08-17 |
| Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT03494569) | City of Hope Medical Center | 2018-07-06 |
| Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS) (NCT03303066) | Kyntra Bio | 2018-06-06 |
| Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 (NCT02890758) | Brenda Cooper, MD | 2018-05-22 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT03358719) | Roswell Park Cancer Institute | 2018-03-27 |
| Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies (NCT03471260) | M.D. Anderson Cancer Center | 2018-03-19 |
| Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome (NCT03337451) | Opsona Therapeutics Ltd. | 2018-02-27 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant (NCT03326921) | Fred Hutchinson Cancer Center | 2018-02-23 |
| Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT03092674) | National Cancer Institute (NCI) | 2018-02-02 |
| Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome (NCT03404193) | M.D. Anderson Cancer Center | 2018-01-18 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer (NCT03333486) | Roswell Park Cancer Institute | 2017-12-07 |
| Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome (NCT03359460) | University of California, Davis | 2017-12-01 |
| Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer (NCT02999854) | Kiadis Pharma | 2017-11-29 |
| Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (NCT03268954) | Takeda | 2017-11-28 |
| Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome (NCT03047993) | M.D. Anderson Cancer Center | 2017-11-15 |
| Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome (NCT03094637) | M.D. Anderson Cancer Center | 2017-11-06 |
| Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers (NCT04484532) | Roswell Park Cancer Institute | 2017-10-17 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma (NCT03096782) | M.D. Anderson Cancer Center | 2017-10-13 |
| Study of SyB C-1101 in Patients With Myelodysplastic Syndrome (NCT03495167) | SymBio Pharmaceuticals | 2017-10-06 |
| Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation (NCT03246906) | Fred Hutchinson Cancer Center | 2017-09-11 |
| Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS (NCT02923986) | Bio-Path Holdings, Inc. | 2017-09-01 |
| Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant (NCT03192397) | Roswell Park Cancer Institute | 2017-08-09 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer (NCT03154190) | Stanford University | 2017-08-08 |
| Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS) (NCT02929498) | GlaxoSmithKline | 2017-07-31 |
| DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess (NCT03356080) | Shanghai Tong Ren Hospital | 2017-07-07 |
| SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (NCT03113643) | Dana-Farber Cancer Institute | 2017-06-26 |
| Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents (NCT02936752) | National Cancer Institute (NCI) | 2017-06-23 |
| Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) (NCT03150004) | Medical College of Wisconsin | 2017-06-14 |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia (NCT03195010) | Fred Hutchinson Cancer Center | 2017-06-09 |
| High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant (NCT03128359) | City of Hope Medical Center | 2017-05-30 |
| Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms (NCT03072043) | H. Lee Moffitt Cancer Center and Research Institute | 2017-05-18 |
| UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep (NCT02722668) | Masonic Cancer Center, University of Minnesota | 2017-05-15 |
| A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (NCT03017820) | Mayo Clinic | 2017-04-04 |
| Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia (NCT03019939) | M.D. Anderson Cancer Center | 2017-03-28 |
| Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome (NCT02943668) | Fred Hutchinson Cancer Center | 2017-03-02 |
| Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02960646) | M.D. Anderson Cancer Center | 2017-01-18 |
| Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide (NCT03088709) | Loyola University | 2017-01-18 |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT02728050) | University of Washington | 2016-12-01 |
| Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed (NCT02935361) | University of Southern California | 2016-11-02 |
| Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls (NCT02809222) | University Hospital, Tours | 2016-10-25 |
| A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) (NCT02842827) | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 2016-10-06 |
| Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms (NCT02756572) | University of Washington | 2016-09-22 |
| A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT02807558) | Syros Pharmaceuticals | 2016-09-20 |